Experience with a new serotonin antagonist in the prevention of migraine
Kollin, E.
Orvosi Hetilap 112(35): 2090 Passim
1971
ISSN/ISBN: 0030-6002 PMID: 5129040 Document Number: 37577
Document emailed within 1 workday
Related Documents
Kusajima, K.; Ozdemir, I.A.; Webb, W.R.; Wax, S.D.; Parker, F.B. 1974: Role of serotonin and serotonin antagonist on pulmonary hemodynamics and microcirculation in hemorrhagic shock Journal of Thoracic and Cardiovascular Surgery 67(6): 908-914Jacquy, J. 1996: Migraine and serotonin: mechanisms and treatments Journal de Pharmacie de Belgique 51(1): 43-46
Lance, J.W.; Anthony, M. 1970: A comparative trial of serotonin antagonists in the management of migraine Proceedings of the Australian Association of Neurologists 7: 31-35
Izzati-zade, K.F.; Chetvertnykh, V.A.; Shutov, A.A. 2011: The morphometric analysis of serotonin granules of platelets in migraine Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 111(10 Part 1): 58-61
Birgus, J.; Nesit, V. 1970: Therapy of pruritus valvae using a serotonin antagonist Ceskoslovenska Gynekologie 35(7): 435-436
Cabral, J.E.; Pontes, J.M.; Toste, M.; Camacho, E.; Leitão, M.C.; Freitas, D.; Monteiro, J.G. 1991: Watermelon stomach: treatment with a serotonin antagonist American Journal of Gastroenterology 86(7): 927-928
Fanchamps, A. 1982: The evolution of thinking about the role and site of action of serotonin in migraine Advances in Neurology 33: 31-33
D'Attoma, G.; Marconi, G.; Nacci, M.G. 1986: Desynchronization of serotonin, hemodynamic equilibrium and the recurrence of migraine crises Minerva Medica 77(30-31): 1445-1447
Mirzoian, R.S.; Seredenin, S.B.; Gan'shina, T.S.; Kostochka, L.M.; Romanycheva, N.A.; Rusakov, D.I. 1998: Tropoxin--a new serotonin antagonist and potential antimigraine agent Eksperimental'naia i Klinicheskaia Farmakologiia 61(3): 28-31
Franz, P.M.; Mattiuz, E.L.; Hatcher, B.L.; DeSante, K.A.; Breau, A.P.; Occolowitz, J.L.; Dorman, D.E.; Schmid, C.R.; Goldberg, M.J.; Rubin, A. 1993: Disposition of zatosetron, a serotonin (5-HT3) receptor antagonist, in humans Drug Metabolism and Disposition: the Biological Fate of Chemicals 21(2): 249-254
Schuck, P.; Böhmer, K.; Resch, K.L. 1999: Migraine and prevention of migraine: the value of magnesium Schweizerische Medizinische Wochenschrift 129(3): 63-70
Goadsby, P.J.; Hargreaves, R.J. 2000: Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan Neurology 55(9 Suppl 2): S8-S14
Engelhardt, G. 1975: On the pharmacology of 9,10-dihydro-10-(1-methyl-4-piperidylidene)-9-anthrol (WA 335), a histamine and serotonin antagonist Arzneimittel-Forschung 25(11): 1723-1737
Jonderko, G.; Neumann, M.; Lewandowski, J.; Słowińska-Primus, B. 1979: Effect of serotonin, histamine and acetylcholine antagonist on serum gastric level Polski Tygodnik Lekarski 34(26): 1037-1038
Tabata, H.; Matsuzawa, T.; Hanada, T.; Ishikawa, A.; Yamada, M.; Ozaki, H.; Izumisawa, N.; Barker, M.H.; Cox, R.A.; Buist, D.P. 1995: Acute, subacute and chronic oral toxicity studies of the new serotonin (5-HT)3-receptor antagonist ramosetron in beagle dogs Arzneimittel-Forschung 45(7): 760-766
Sulman, F.G.; Pfeifer, Y.; Superstine, E. 1981: Preventive treatment of serotonin-migraine with 1,3,4,14b-tetrahydro-2,7-dimethyl-2H-dibenzo(b,f)pyrazino-(1,2--d)-(1,4)-oxazepine hydrogen maleate (Org GC 94). A double-blind study Arzneimittel-Forschung 31(1): 109-112
Ledić, P.; Antoncić, N.; Sepcić, J. 1973: BC-105 in the prevention of migraine Neuropsihijatrija 21(3-4): 291-296
Heuser, B.; Middendorf, E. 1985: Migraine prevention with dihydroergotamine Fortschritte der Medizin 103(41): 966-970
Diener, H.C. 2006: Migraine prevention with Petasites Medizinische Monatsschrift für Pharmazeuten 29(1): 40
Bermejo Velasco, P.Emilio.; Velasco Calvo, Río. 2007: New antiepileptic drugs in migraine prevention Medicina Clinica 128(10): 379-382